Month: June 2022

SOLANA BEACH, Calif., June 01, 2022 (GLOBE NEWSWIRE) —  Artelo Biosciences, Inc. “Artelo” or the “Company”) (NASDAQ: ARTL), a clinical-stage pharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, today announced that Gregory D. Gorgas, Chief Executive Officer of Artelo, will be presenting at the LD Micro conference which is being held on June 7– 9, 2022, at the Four Seasons Westlake Village, California. Mr. Gorgas is scheduled to present on Tuesday, June 7, 2022, at 2:30 P.M PT/ 5:30 P.M. ET. The presentation will be webcast live and available for replay at ldinv12.mysequire.com. Management will also be available for one-on-one meetings with qualified investors June 7 and 8, 2022 during the conference.   About Artelo Biosciences Artelo Biosciences, Inc. is a...

Microsoft Azure customers worldwide may access Duck Creek OnDemand and leverage the company’s cloud-based capabilities to remain agile, intelligent and evergreen Boston, June 01, 2022 (GLOBE NEWSWIRE) — Duck Creek Technologies (NASDAQ: DCT), a leading, global technology solutions provider to the property and casualty (P&C) insurance industry, today announces the availability of Duck Creek OnDemand, its cloud-based software-as-a-service (SaaS) solution, in the Microsoft Azure Marketplace. P&C insurance carriers with an existing Microsoft Azure Consumption Commitment (MACC) may fully utilize newly contracted Duck Creek OnDemand spend to contribute to their Azure commitment. Duck Creek offers policy, rating, billing, claims, producer, insights, distribution management, and industry content solutions in the Microsoft Azure...

OTTAWA, June 01, 2022 (GLOBE NEWSWIRE) — Cornerstone Capital Resources Inc. (“Cornerstone” or “the Company”) (TSXV:CGP; OTC:CTNXF; FWB:GWN1) is pleased to provide an update on its Bramaderos gold and copper joint venture in southern Ecuador (see Figures 1 and 2) in which it has a 12.5% interest carried by JV partner and project operator Sunstone Metals Ltd. (ASX: STM) through to the start of commercial production (see “About Bramaderos”, below). Figures related to this news release can be seen in PDF format by accessing the version of this release on the Company’s website (www.cornerstoneresources.com) or by clicking on the link below: https://cornerstoneresources.com/site/assets/files/5855/nr22-13figures.pdf. HIGHLIGHTS:Strong assay results received from Brama for holes BMDD0014, 015, 016, 017, and 018:221.6m at 0.43g/t gold,...

Benet Rupp Benet Rupp Promoted to Chief Administrative OfficerShalini Singhal Shalini Singhal, Chief Information Officer, to Lead M&A IntegrationsAlexis Smith Alexis Smith Promoted to Chief People OfficerAmy Cover Amy Cover Promoted to Chief Marketing OfficeMolly Miller Molly Miller Promoted to Senior E-Banking & Product Lifecycle ManagerBenet Rupp Promoted to Chief Administrative Officer Shalini Singhal, Chief Information Officer, to Lead M&A Integrations Alexis Smith Promoted to Chief People Officer Amy Cover Promoted to Chief Marketing Officer Molly Miller Promoted to Senior E-Banking & Product Lifecycle ManagerARCHBOLD, Ohio, June 01, 2022 (GLOBE NEWSWIRE) — Farmers & Merchants Bancorp, Inc., (Nasdaq: FMAO) announces the retirement of Edward A. Leininger EVP & Chief Operating...

Cranbury, NJ, June 01, 2022 (GLOBE NEWSWIRE) — Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced that the Company and its partners will present three abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 3 – June 7, 2022 in Chicago. The three abstracts from Cornerstone’s partners and principal investigators, Mark Agulnik, Vaibhav Sahai and Philip Philip, highlight its ongoing trials studying CPI-613® (devimistat) in clear cell sarcoma and biliary tract cancer, with a special discussion on pancreatic cancer. “We are incredibly proud to have promising research findings to share in the three rare cancer areas that we’re focused on at ASCO’s Annual Meeting,” said Sanjeev...

CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences: Jefferies Healthcare ConferencePresentation date: Wednesday, June 8, 2022Presentation time: 2:30 PM ETLocation: Marriott Marquis, New York, NY Goldman Sachs 43rd Annual Global Healthcare Conference Dates: June 13-16, 20221×1 meetings onlyLocation: Terranea Resort, Ranch Palos Verdes, CA JMP Securities Life Sciences ConferenceFireside Chat date: Thursday, June 16, 2022Presentation time: 11:00 AM ETLocation: The Lotte New York Palace Hotel, New York, NY Stifel’s 2022 Virtual Cell Therapy SummitDates: June 29-30, 2022 Live webcasts and archived replays of key presentations will be available on the Company’s...

ENCINITAS, Calif., June 01, 2022 (GLOBE NEWSWIRE) — Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced that Raju Mohan, Chief Executive Officer of Ventyx, will provide a company overview during a fireside chat at the Jefferies Healthcare Conference being held June 8-10, 2022.Event: Jefferies Healthcare ConferenceLocation: New York, NYDate: Wednesday, June 8, 2022Time: 4:00-4:25 PM ETMembers of the Ventyx management team will also host investor meetings during the conference. A webcast of the fireside chat will be available in the Investors and News section of the Ventyx website at www.ventyxbio.com. A webcast replay will also be available on...

Atos, UCL and Arm team up to offer wider cloud computing possibilities for life sciences applications Paris, France – June 1st, 2022 – Atos and UCL today announce having successfully run the virus sequencing tool, Viridian, which is used to detect mutation of the SARS-Cov-2 strain of the coronavirus, using an Arm®-based Ampere® Altra® processor in a cloud native environment with Atos’ integration expertise. This proof of concept (PoC) was coordinated by Atos’ Life Sciences Center of Excellence which aims to foster a culture of exploration, discovery and co-creation to harness the power of digital technologies in order to advance precision health and accelerate the discovery and development of drugs. With data growing exponentially and becoming more difficult to process for life sciences applications, data, scientists rely on high-performance...